Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
Charles D Ericsson

Abstract

Although travellers' diarrhoea can sometimes be associated with postinfectious complications, the condition is typically self-limiting. The infectious-diarrhoea guidelines subcommittees of the Infectious Disease Society of America and the American College of Gastroenterology recommend empirical antibacterial therapy for travellers' diarrhoea. Because therapy is directed largely at relieving symptoms and minimising inconvenience, the chosen antibacterial should ideally be both efficacious and pose a low risk of adverse effects. This review discusses the safety and tolerability of rifaximin in the treatment of travellers' diarrhoea, with a focus on data from controlled clinical trials. Data were obtained from a MEDLINE search using the key word 'rifaximin' with no date limits and from the rifaximin New Drug Application submitted to the US FDA for approval to market rifaximin in the US.Currently, the antibacterials considered as standard treatment for travellers' diarrhoea are systemically absorbed, carry defined risks of adverse effects, and have many uses other than the treatment of enteric disease. The minimally absorbed (<0.4%) oral antibacterial rifaximin constitutes a non-systemic approach to antidiarrhoeal therapy that shou...Continue Reading

References

Apr 8, 1992·JAMA : the Journal of the American Medical Association·H L DuPontD A Conrad
Jan 1, 1983·Annals of Internal Medicine·C D EricssonD J Evans
Nov 23, 1995·The New England Journal of Medicine·J H ReesR A Hughes
Jun 24, 1993·The New England Journal of Medicine·H L DuPont, C D Ericsson
May 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C D Ericsson, H L DuPont
Sep 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R A KuschnerD N Taylor
Mar 21, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C W HogeP Echeverria
Nov 14, 1998·Digestion·H L DuPontF J de la Cabada
May 20, 1999·The New England Journal of Medicine·K E SmithM T Osterholm
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R L GuerrantUNKNOWN Infectious Diseases Society of America
Mar 28, 2001·Antimicrobial Agents and Chemotherapy·J M SierraJ Vila
Apr 6, 2001·The American Journal of Tropical Medicine and Hygiene·D R Hill
Nov 3, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·H L DuPontF Martinez-Sandoval
Feb 1, 1997·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Ornella SoroGian Carlo Schito
Jun 18, 2003·The American Journal of Gastroenterology·Robert SteffenHerbert L DuPont
Nov 4, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H L DuPont, Z-D Jiang

❮ Previous
Next ❯

Citations

May 20, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Corrado BlandizziCarmelo Scarpignato
May 16, 2009·Expert Opinion on Drug Metabolism & Toxicology·Veronica OjettiAntonio Gasbarrini
Oct 28, 2019·Critical Reviews in Food Science and Nutrition·Rosanna TofaloCharles M A P Franz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
David N Taylor
© 2021 Meta ULC. All rights reserved